Bioelectrochemistry and new biomedical array technologies

James F. Rusling Professor of Chemistry and Cell Biology University of Connecticut and University Health Center Neag Comprehensive Cancer Center SFI Walton Research Fellow, NUI Galway

Website: http://web2.uconn.edu/rusling/ Email: James.Rusling@uconn.edu



BIOELECTROCHEMISTRY: Protein Film Voltammetry



Khrisna Alcantara, Bernard Munge, Zeus Pendon, Harry A. Frank, and James F. Rusling, "Thin Film Voltammetry of **Spinach Photosystem II**. Proton-gated electron transfer involving the Mn₄ cluster" J. Am. Chem. Soc., **2006**, 128, 14930-14937. *Funded by NSF, with H.A. Frank*

Yun Zhang, Amy M. LaFountain, Nikki Magdaong, Marcel Fuciman, James P. Allen, Harry A. Frank, and James F. Rusling, Thin Film Voltammetry of Wild Type and Mutant Reaction Center Proteins from Photosynthetic Bacteria, *J. Phys. Chem. B*, 2011, 115, 3226–3232.

Human Metabolic Enzymes: funded by NIH

- cytochrome P450s oxidative catalysts
- bioconjugation enzymes
- toxicity screening arrays



Prof. John Schenkman, Pharmacology, Cell Biology, Uconn Health Center



Sadagopan Krishnan, John B. Schenkman and James F Rusling, *Feature Article*: Bioelectronic Delivery of Electrons to Cytochrome P450 Enzymes. *J. Phys. Chem. B* **2011**, *115* 8371–8380. dx.doi.org/10.1021/jp201235m

316. Sadagopan Krishnan, Dhanuka Wasalathanthri, Linlin Zhao, John B. Schenkman, and James F. Rusling, Efficient Bioelectronic Actuation of the Natural Catalytic Pathway of Human Metabolic Cytochrome P450s, J. Am. Chem. Soc., **2011**, 133, 1459–1465.

Chemical toxicity: a critical public health problem

- New drugs & environmental chemicals must be proven safe.
- \$2 billion to develop a single drug!
- clinical failures approach 30% due to toxicity
- existing bioassays give <u>no structural details</u>
- animal models often fail; interspecies differences

• <u>Our approaches</u> - electro-optical arrays, LC-MS/MS, CE-LIF





ECL ARRAY with CCD camera for detection

Funded by NIH

Using rat or human liver microsomes as multi-enzyme sources



Screening for Reactive Metabolites



 $RuPVP^{2+} = RuPVP^{3+} + e- (in film)$ $RuPVP^{3+} + DNA-G --> [RuPVP^{2+}]^* + DNA-Gox$ \downarrow $RuPVP^{2+} + light$

Films contain enzymes, RuPVP and DNA

Microsomes are multi-enzyme source in ECL arrays



S. Krishnan, B. Bajrami, E. G. Hvastkovs, D. Choudhary, J. B. Schenkman, and J. F. Rusling, Synergistic Metabolic Toxicity Screening Using Microsome/DNA Electrochemiluminescent Arrays and Nanoreactors, *Anal Chem.*, **2008**, *80*, 5279–5285.



Scheme 1. Bioanalytical system for *in vitro* metabolic profiling and toxicity screening

Linlin Zhao, John B. Schenkman and James F. Rusling, High Throughput Metabolic Toxicity Screening Using Magnetic Biocolloid Reactors and LC-MS/MS, Anal. Chem., **2010**, 82, 10172–10178.



SRM-MS/MS chromatograms measuring total ion current for predominant guanine adducts (m/z shown in inset) produced via exposure of a) NPYR, b) NNK, and c) NPIP to RLM/DNA nanoreactors followed by neutral thermal DNA hydrolysis. Inset shows guanine adduct and fragmentation pattern consistent with each chromatogram. d) Integrated peak area measured by UV detection increased for NPYR-guanine adducts with reaction time from both RLM and h2E1 films. Substrates: 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK), N-nitrosopiperidine (NPIP), and N-nitrosopyrrolidine (NPYR).

Nanoparticle-Based Arrays for Sensitive Detection of Cancer Biomarker Proteins

- Ultrasensitive detection of multiple cancer biomarkers
- Long term objectives
 - 1. early cancer detection, therapy monitoring
 - 2. tools for cancer research; surgical decisions



Dr. Vyomesh Patel

Dr. Silvio Gutkind National Institutes of Health,



Prof. Fotios Papadimitrakopoulos, Inst. Materials Sci., Univ. of Connecticut

Funded by NIH

Biomarker Targets: 1. Prostate Specific Antigen



Adapted From Brookhaven Protein Databank

PSA - Single chain
glycoprotein , MW 33 kDa.
Biomarker for prostate
cancer

Detection of PSA in serum: clinical detection of prostate cancer: 4-10 ng/mL, normal <3 ng/mL in serum</p>

Less invasive treatment protocols, avoid surgery

2. Interleukin 6 (IL-6)

_ prostate and oral cancer biomarker

-human plasma conc. normal < 6 pg/mL; cancer 20-1000 pg/mL

Off-line capture by magnetic particles, microfluidic array







(a) pump, injector and 8-electrode microfluidic array with approximate electrode arrangement at top left

Microfluidic array data with off-line capture of PSA and IL-6 in serum, ~200,000 labels



Flow rate : $100 \mu L/min$ H_2O_2 : $100 \mu M$ Hydroquinone : 1 mM

Limit of detection of PSA: 0.23 pg/mL Limit of detection of IL6 : 0.30 pg/mL

Immunosensor assay validation on human serum Good agreement with ELISA (std assay, one protein/run)



Bhaskara V. Chikkaveeraiah, Vigneshwaran Mani, Vyomesh Patel, J. Silvio Gutkind, and James F. Rusling, Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum, *Biosensors & Bioelectron*. **2011**, *26*, 4477–4483.



Oral cancer and normal cell conditioned media

Other methods of protein detection

ECL arrays for detection of PSA and IL-6



Surface plasmon resonance (SPR) using superparamagnetic bead labels (with CV Kumar)



Our Univ. of Connecticut group, Dec. 2011

